In this virtual tumor board, the participants will hear a case-based discussion that will include:

• Molecular profiling of tumors and how the emerging role of immunotherapy can impact the management of soft tissue sarcoma patients.
• The relationship of gastrointestinal stromal tumor (GIST) mutational status with systemic treatment selection.
• The role of anaplastic lymphoma kinase (ALK) inhibitors as a treatment option for ALK positive inflammatory myofibroblastic tumor (IMT).
• Situations where next-generation sequencing (NGS) might identify potential novel treatment targets.

Indications for immunotherapy in select soft tissue sarcoma patients.

Moderating this session will be John Kane, MD, Roswell Park Comprehensive Cancer Center

Panelists:
John Mullinax, MD, Moffitt Cancer Center
Christina L. Roland MD, MS, The University of Texas MD Anderson Cancer Center
David Kirsch, MD, PhD, Duke Cancer Institute
Katherine Thornton, MD, Memorial Sloan Kettering Cancer Center